Mind Medicine (MindMed) (MNMD) Competitors $9.61 -0.11 (-1.13%) Closing price 08/15/2025 04:00 PM EasternExtended Trading$9.61 +0.00 (+0.01%) As of 08/15/2025 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipShort InterestTrendsBuy This Stock MNMD vs. IMVT, RARE, ALVO, CPRX, CRNX, MIRM, GMTX, XENE, OGN, and AMRXShould you be buying Mind Medicine (MindMed) stock or one of its competitors? The main competitors of Mind Medicine (MindMed) include Immunovant (IMVT), Ultragenyx Pharmaceutical (RARE), Alvotech (ALVO), Catalyst Pharmaceuticals (CPRX), Crinetics Pharmaceuticals (CRNX), Mirum Pharmaceuticals (MIRM), Gemini Therapeutics (GMTX), Xenon Pharmaceuticals (XENE), Organon & Co. (OGN), and Amneal Pharmaceuticals (AMRX). These companies are all part of the "pharmaceutical products" industry. Mind Medicine (MindMed) vs. Its Competitors Immunovant Ultragenyx Pharmaceutical Alvotech Catalyst Pharmaceuticals Crinetics Pharmaceuticals Mirum Pharmaceuticals Gemini Therapeutics Xenon Pharmaceuticals Organon & Co. Amneal Pharmaceuticals Mind Medicine (MindMed) (NASDAQ:MNMD) and Immunovant (NASDAQ:IMVT) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, profitability, valuation, institutional ownership, earnings, media sentiment, risk and dividends. Which has more volatility and risk, MNMD or IMVT? Mind Medicine (MindMed) has a beta of 2.49, indicating that its share price is 149% more volatile than the S&P 500. Comparatively, Immunovant has a beta of 0.66, indicating that its share price is 34% less volatile than the S&P 500. Is MNMD or IMVT more profitable? Mind Medicine (MindMed)'s return on equity of -50.24% beat Immunovant's return on equity.Company Net Margins Return on Equity Return on Assets Mind Medicine (MindMed)N/A -50.24% -39.41% Immunovant N/A -80.99%-72.23% Do insiders & institutionals hold more shares of MNMD or IMVT? 27.9% of Mind Medicine (MindMed) shares are owned by institutional investors. Comparatively, 47.1% of Immunovant shares are owned by institutional investors. 2.5% of Mind Medicine (MindMed) shares are owned by insiders. Comparatively, 1.8% of Immunovant shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth. Does the media prefer MNMD or IMVT? In the previous week, Immunovant had 24 more articles in the media than Mind Medicine (MindMed). MarketBeat recorded 27 mentions for Immunovant and 3 mentions for Mind Medicine (MindMed). Immunovant's average media sentiment score of 0.44 beat Mind Medicine (MindMed)'s score of 0.33 indicating that Immunovant is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Mind Medicine (MindMed) 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Immunovant 3 Very Positive mention(s) 3 Positive mention(s) 2 Neutral mention(s) 6 Negative mention(s) 0 Very Negative mention(s) Neutral Do analysts rate MNMD or IMVT? Mind Medicine (MindMed) currently has a consensus price target of $24.71, suggesting a potential upside of 157.17%. Immunovant has a consensus price target of $35.20, suggesting a potential upside of 131.27%. Given Mind Medicine (MindMed)'s stronger consensus rating and higher possible upside, research analysts clearly believe Mind Medicine (MindMed) is more favorable than Immunovant.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Mind Medicine (MindMed) 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 2 Strong Buy rating(s) 3.22Immunovant 0 Sell rating(s) 3 Hold rating(s) 8 Buy rating(s) 1 Strong Buy rating(s) 2.83 Which has stronger earnings and valuation, MNMD or IMVT? Mind Medicine (MindMed) is trading at a lower price-to-earnings ratio than Immunovant, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMind Medicine (MindMed)N/AN/A-$108.68M-$1.53-6.28ImmunovantN/AN/A-$413.84M-$2.85-5.34 SummaryMind Medicine (MindMed) beats Immunovant on 9 of the 14 factors compared between the two stocks. Get Mind Medicine (MindMed) News Delivered to You Automatically Sign up to receive the latest news and ratings for MNMD and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding MNMD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MNMD vs. The Competition Export to ExcelMetricMind Medicine (MindMed)MED IndustryMedical SectorNASDAQ ExchangeMarket Cap$739.58M$3.09B$5.66B$9.82BDividend YieldN/A2.23%3.79%4.07%P/E Ratio-6.2820.3830.5825.12Price / SalesN/A364.65464.66115.60Price / CashN/A42.3037.4059.05Price / Book3.948.659.096.18Net Income-$108.68M-$54.65M$3.25B$264.89M7 Day Performance-2.44%6.58%7.32%4.18%1 Month Performance12.00%7.54%5.42%1.99%1 Year Performance51.10%13.73%30.66%24.22% Mind Medicine (MindMed) Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MNMDMind Medicine (MindMed)2.4561 of 5 stars$9.61-1.1%$24.71+157.2%+49.7%$739.58MN/A-6.2840IMVTImmunovant2.9059 of 5 stars$16.09+2.4%$36.40+126.2%-50.7%$2.75BN/A-5.87120News CoveragePositive NewsEarnings ReportAnalyst ForecastAnalyst RevisionRAREUltragenyx Pharmaceutical4.6668 of 5 stars$28.46+0.1%$83.08+191.9%-42.6%$2.69B$560.23M-4.841,294ALVOAlvotech2.7885 of 5 stars$8.87+0.9%$14.00+57.8%-32.8%$2.67B$491.98M23.971,032Trending NewsEarnings ReportShort Interest ↓CPRXCatalyst Pharmaceuticals4.8868 of 5 stars$21.73+2.9%$32.83+51.1%+1.6%$2.65B$491.73M13.8480CRNXCrinetics Pharmaceuticals3.4654 of 5 stars$28.22+1.4%$69.50+146.3%-41.5%$2.64B$760K-7.39210Gap UpMIRMMirum Pharmaceuticals3.4338 of 5 stars$52.24+0.4%$65.50+25.4%+63.6%$2.59B$379.25M-32.45140Insider TradeGMTXGemini TherapeuticsN/A$58.97-1.3%N/A+34.0%$2.56BN/A-58.9730XENEXenon Pharmaceuticals2.0494 of 5 stars$33.16+8.7%$54.82+65.3%-0.1%$2.54B$9.43M-10.27210Trending NewsEarnings ReportAnalyst ForecastAnalyst RevisionHigh Trading VolumeOGNOrganon & Co.4.6991 of 5 stars$9.68-0.7%$18.00+86.0%-53.4%$2.52B$6.29B3.364,000AMRXAmneal Pharmaceuticals3.0725 of 5 stars$7.96+1.7%$11.60+45.7%+19.5%$2.49B$2.79B-198.958,100News CoverageInsider Trade Related Companies and Tools Related Companies IMVT Alternatives RARE Alternatives ALVO Alternatives CPRX Alternatives CRNX Alternatives MIRM Alternatives GMTX Alternatives XENE Alternatives OGN Alternatives AMRX Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:MNMD) was last updated on 8/16/2025 by MarketBeat.com Staff From Our PartnersGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredMusk’s Project Colossus could mint millionairesI predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...Brownstone Research | SponsoredGenesis 14:13-17 [HIDDEN MEANING?]A mysterious Bible verse from Genesis may hold the key to unlocking what one expert calls an “American birthri...Paradigm Press | SponsoredTrump's New Plan to “Make China Pay”Trump's AI Masterplan Could Crush China The White House just unleashed would could be the most aggressive e...Stansberry Research | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | SponsoredCrypto Income (almost instantly)How would you like to collect a small percentage of the $4 billion changing hands daily in the crypto market? ...Awesomely, LLC | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Mind Medicine (MindMed) Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Mind Medicine (MindMed) With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access